Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 237

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Genomic Methods Identify Homologous Recombination Deficiency in Pancreas Adenocarcinoma and Optimize Treatment Selection

Open access
Park, Wungki, Chen, Jiapeng, Chou, Joanne F., Varghese, Anna M., Yu, Kenneth H., Wong, Winston, Capanu, Marinela, Balachandran, Vinod, McIntyre, Caitlin A., El Dika, Imane, Khalil, Danny N., Harding, James J., Ghalehsari, Nima, McKinnell, Zoe, Chalasani, Sree B., Makarov, Vladimir, Selenica, Pier, Pei, Xin, Lecomte, Nicolas, Kelsen, David P., Abou-Alfa, Ghassan K., Robson, Mark E., Zhang, Liying, Berger, Michael F., Schultz, Nikolaus, Chan, Timothy A., Powell, Simon N., Reis-Filho, Jorge S., Iacobuzio-Donahue, Christine A., Riaz, Nadeem, O'Reilly, Eileen M. · 2020 · Clinical Cancer Research

Abstract

Purpose: Genomic methods can identify homologous recombination deficiency (HRD). Rigorous evaluation of their outcome association to DNA damage response–targeted therapies like platinum in pancreatic ductal adenocarcinoma (PDAC) is essential in maximizing therapeutic outcome. Experimental Design: We evaluated progression-free survival (PFS) and overall survival (OS) of patients with advanced-stage PDAC, who had both germline- and somatic-targeted gene sequencing. Homologous recombination gene mutations (HRm) were evaluated: BRCA1, BRCA2, PALB2, ATM, BAP1, BARD1, BLM, BRIP1, CHEK2, FAM175A, FANCA, FANCC, NBN, RAD50, RAD51, RAD51C, and RTEL1 HRm status was grouped as: (i) germline versus somatic; (ii) core (BRCAs and PALB2) versus non-core (other HRm); and (iii) monoallelic versus biallelic. Genomic instability was compared using large-scale state transition, signature 3, and tumor mutation burden. Results: Among 262 patients, 50 (19%) had HRD (15% germline and 4% somatic). Both groups were analyzed together due to lack of difference in their genomic instability and outcome. Median [95% confidence interval (CI)] follow-up was 21.9 (1.4–57.0) months. Median OS and PFS were 15.5 (14.6–19) and 7 (6.1–8.1) months, respectively. Patients with HRD had improved PFS compared with no HRD when treated with first-line (1L) platinum [HR, 0.44 (95% CI: 0.29–0.67); P < 0.01], but not with 1L-non-platinum. Multivariate analysis showed HRD patients had improved OS regardless of their first-line treatment, but most had platinum exposure during their course. Biallelic HRm (11%) and core HRm (12%) had higher genomic instability, which translated to improved PFS on first-line platinum (1L-platinum) versus 1L-non-platinum. Conclusions: Pathogenic HRm identifies HRD in patients with PDAC with the best outcome when treated with 1L-platinum. Biallelic HRm and core HRm further enriched benefit from 1L-platinum from HRD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-20-0418

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Cited by

See all 237

Metadata

Authors
Park, W., Chen, J., Chou, J. F., Varghese, A. M., Yu, K. H., Wong, W., Capanu, M., Balachandran, V., McIntyre, C. A., El Dika, I., Khalil, D. N., Harding, J. J., Ghalehsari, N., McKinnell, Z., Chalasani, S. B., Makarov, V., Selenica, P., Pei, X., Lecomte, N., Kelsen, D. P., Abou-Alfa, G. K., Robson, M. E., Zhang, L., Berger, M. F., Schultz, N., Chan, T. A., Powell, S. N., Reis-Filho, J. S., Iacobuzio-Donahue, C. A., Riaz, N., & O'Reilly, E. M.
Venue
Clinical Cancer Research
Published
2020-07-01
Volume
26
Issue
13
Pages
3239-3247
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W3028410510
Cited by
237
References
15
FWCI
10.99
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Genomic Methods Identify Homologous Recombination Deficiency in Pancreas Adenocarcinoma and Optimize Treatment Selection. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-20-0418
The paper
Park, W., Chen, J., Chou, J. F., Varghese, A. M., Yu, K. H., Wong, W., Capanu, M., Balachandran, V., McIntyre, C. A., El Dika, I., Khalil, D. N., Harding, J. J., Ghalehsari, N., McKinnell, Z., Chalasani, S. B., Makarov, V., Selenica, P., Pei, X., Lecomte, N., . . . O'Reilly, E. M. (2020). Genomic Methods Identify Homologous Recombination Deficiency in Pancreas Adenocarcinoma and Optimize Treatment Selection. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-20-0418

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.